AQR Capital Management
STOK icon

AQR Capital Management’s Stoke Therapeutics STOK Stock Holding History

AQR Capital Management’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$865K Sell
26,449
-20,010
-43% -$642K ﹤0.01% 3087
2026
Q1 		$1.51M Buy
46,459
+16,992
+58% +$557K ﹤0.01% 2538
2025
Q4 		$935K Buy
29,467
+354
+1% +$10.6K ﹤0.01% 2597
2025
Q3 		$684K Sell
29,113
-25,705
-47% -$440K ﹤0.01% 2651
2025
Q2 		$622K Buy
54,818
+41,971
+327% +$399K ﹤0.01% 2484
2025
Q1 		$85.4K Sell
12,847
-10,772
-46% -$100K ﹤0.01% 3036
2024
Q4 		$261K Sell
23,619
-51,470
-69% -$632K ﹤0.01% 2565
2024
Q3 		$923K Buy
+75,089
New +$1.06M ﹤0.01% 1889

Other funds holding STOK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AQR Capital Management's STOK Position: Q2 2026 in Review

AQR Capital Management reduced its Stoke Therapeutics (STOK) stake by 43% in Q2 2026, selling an estimated $642K and leaving 26,449 shares worth $865K. The position accounts for ﹤0.01% of the portfolio, ranked #3087.

AQR Capital Management first reported a position in STOK in Q3 2024 and has held it in 8 quarters since. The position peaked at $1.51M in Q1 2026. 197 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • AQR Capital Management held 26,449 shares of Stoke Therapeutics worth $865K as of Q2 2026.
  • AQR Capital Management sold 20,010 Stoke Therapeutics shares in Q2 2026, an estimated $642K.
  • Stoke Therapeutics made up ﹤0.01% of AQR Capital Management's portfolio in Q2 2026, its #3087 holding.
  • AQR Capital Management first reported a position in Stoke Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • AQR Capital Management's Stoke Therapeutics position peaked at $1.51M in Q1 2026.
  • 197 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.